Mizuho Raises Price Target for Corbus Pharmaceuticals (CRBP) Amid Positive Outlook

Mizuho Financial has raised its price target for Corbus Pharmaceuticals (CRBP) to $40, citing strong risk-reward potential as the stock trades near the company’s cash position. The firm highlights upcoming clinical data readouts in 2026 and progress in FDA alignment for CRB-701 as key catalysts.

By Laiba Immad Fri, April 17, 2026 at 4:58 PM GMT+3 2 min read · Yahoo Finance · April 17, 2026, 13:58 UTC

Tickers: $CRBP

Topics: analyst upgrade biotech clinical trials FDA approval leadership change stock analysis

Read the full article at Yahoo Finance

More World news

Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC
DPC Holdings PLC Reports Record Q3 Revenue Growth and Issues 2027 Financial Guidance Seeking Alpha · November 12, 2026, 19:01 UTC
Senate Minority Leader Schumer Demands Congressional Testimony from Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 18:59 UTC
Nvidia Shares Plunge Following CEO Jensen Huang's Departure Amid Investigation Motley Fool · November 12, 2026, 19:00 UTC
San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity Seeking Alpha · November 12, 2026, 19:00 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC